强耀生物科技
强耀生物
强耀生物
强耀生物科技version: English | 中文版
强耀生物科技
强耀生物科技
Online Service 
强耀生物科技
强耀生物科技
Scan For WeChat
强耀生物科技
Phone Web

Services
Products强耀生物科技
强耀生物
Your location:Home>> Products >> Hot Polypeptide

强耀生物科技 Fibronectin cs1 Peptide
Name Fibronectin cs1 Peptide
Other Name CS1 peptide of fibronectin
Sequence (Single letter abbreviations) EILDVPST
Sequence(Three letter abbreviations) {GLU}{ILE}{LEU}{ASP}{VAL}{PRO}{SER}{THR}
Basic description The connecting segment 1 (CS-1) is a cell attachment domain located in the type III homology connecting segment (IIICS) of fibronectin. CS1 peptide of fibronectin, which lacks the Arg-Gly-Asp-containing domain, actively inhibits tumor metastases in spontaneous and experimental metastasis models. The use of Fibronectin CS1 Peptide might offer a promising therapeutic approach for combating and preventing cancer metastasis.
Solubility The peptide is soluble in water. The contents of this vial have been accurately determined. Both the stopper and the vial have been siliconized. Do not attempt to weigh out a smaller portion of the contents.
The molecular weight 872.960
Chemical formula C38H64N8O15
The purity > 95%
Storage conditions Before use, store the peptide in the DRY form at 0-5°C. For and more repeatable results, rehydrate the peptide immediately before use. Do not re-freeze any unused portions.
Annotation This peptide is part of the fibronectin receptor which is identical to the integrin receptor of α4 β1. It completely inhibits lymphocyte adhesion to CS1 and partially inhibits adhesion to intact fibronectin. The 38,000 Da fragment and has no effect on lymphocyte adhesion to an 80,000 Da fragment containing the RCDS adhesion null.
Documents 文档
Figures
Reference Vaz R., etc. Fibronectin promotes migration, alignment and fusion in an in vitro myoblast cell model. Cell Tissue Res. 2012 Jun;348(3):569-78.


Contact Us    |    Jobs    |    About Us    |    My Account   
TEL:021-50795728 0512-63930660 E-MAIL: outside@ChinaPeptides.com
COPYRIGHT © 2009 ChinaPeptides CORPORATION. ALL RIGHTS RESERVED